argumentA line of reasoning from premises to a conclusion. Like a claim, it belongs to no one who makes it.constitution →

Null result in the largest trial

againstThis argument, if it holds, weighs against the claim.constitution →Colchicine reduces cardiovascular events in patients with coronary artery disease

The argument

Because the CLEAR SYNERGY trial, the largest colchicine outcomes trial, found no reduction in cardiovascular events after myocardial infarction despite lowering C-reactive protein, the earlier positive results may reflect chance or bias rather than a true effect, and any real benefit is at most modest. Null results from colchicine trials in stroke patients (CONVINCE, CHANCE-3) point the same way.

Does it work?

Does it follow?: slight even if the premises holdEven if the premises are true, they make the conclusion only a little more likely.constitution →
Do the premises hold?: 1 not separately assessed

If the CLEAR SYNERGY null result holds, it lowers confidence in a benefit after myocardial infarction and suggests that any effect is smaller than the early trials indicated. It does not establish that there is no effect. Pooled analyses that include it remain positive, and it says little about chronic coronary disease. The stroke trials studied a different population, so they add little to the argument.

Premises

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →In the CLEAR SYNERGY trial, colchicine did not reduce cardiovascular events after myocardial infarction

Where it is made

Passages where sources make, criticize or mention this argument. They record where it appears, not how strong it is, and none has precedence over another.

No source is recorded as making it.

Earlier ratings

Aug 7, 2026
The inference goes through in weakened form: a null result in the largest trial genuinely undercuts confidence in the earlier positive findings and caps the plausible effect size, but it does not by itself show those findings were chance or bias, since pooled analyses including the null trial still estimate a reduction. The argument lives on the CLEAR SYNERGY null result, which is not disputed as a trial finding; what remains contested is how to reconcile it with the positive trials, with proposed explanations (low event rate, discontinuation, incomplete inflammation suppression) still post hoc. The stroke-trial nulls cited in support concern a different population and add only indirect weight.